Fibronectin expression is upregulated by PI-3K/Akt activation in tamoxifen-resistant breast cancer cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | You, Daeun | - |
dc.contributor.author | Jung, Seung Pil | - |
dc.contributor.author | Jeong, Yisun | - |
dc.contributor.author | Bae, Soo Youn | - |
dc.contributor.author | Lee, Jeong Eon | - |
dc.contributor.author | Kim, Sangmin | - |
dc.date.accessioned | 2021-09-02T22:14:19Z | - |
dc.date.available | 2021-09-02T22:14:19Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-12 | - |
dc.identifier.issn | 1976-6696 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/81284 | - |
dc.description.abstract | Fibronectin (FN) plays important roles in the EMT in a variety of cancer cell types. However, the mechanism by which FN expression is regulated in tamoxifen-resistant (TamR) breast cancer cells has not yet been fully elucidated. Aberrant FN expression was associated with poor prognosis in patients with luminal type A breast cancer. In addition, FN was upregulated in TamR cells. To investigate the mechanism by which FN expression is regulated, we assessed the levels of phosphorylated Akt, JNK, and STAT3 and found that they were all increased in TamR cells. Induction of FN expression was dampened by LY294002 or AKT IV in TamR cells. Furthermore, FN expression was increased by constitutively active (CA)-Akt overexpression in tamoxifen-sensitive MCF7 (TamS) cells and colony formation of TamR cells was blocked by AKT IV treatment. Taken together, these results demonstrate that FN expression is upregulated through the PI-3K/Akt pathway in tamoxifen-resistant breast cancer cells. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY | - |
dc.subject | EPIDERMAL-GROWTH-FACTOR | - |
dc.subject | NF-KAPPA-B | - |
dc.subject | RECEPTOR | - |
dc.subject | INDUCTION | - |
dc.subject | GENE | - |
dc.subject | INVASION | - |
dc.subject | MUTATIONS | - |
dc.subject | OVARIAN | - |
dc.title | Fibronectin expression is upregulated by PI-3K/Akt activation in tamoxifen-resistant breast cancer cells | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jung, Seung Pil | - |
dc.contributor.affiliatedAuthor | Bae, Soo Youn | - |
dc.identifier.doi | 10.5483/BMBRep.2017.50.12.096 | - |
dc.identifier.scopusid | 2-s2.0-85040056546 | - |
dc.identifier.wosid | 000419131500005 | - |
dc.identifier.bibliographicCitation | BMB REPORTS, v.50, no.12, pp.615 - 620 | - |
dc.relation.isPartOf | BMB REPORTS | - |
dc.citation.title | BMB REPORTS | - |
dc.citation.volume | 50 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 615 | - |
dc.citation.endPage | 620 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002295432 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.subject.keywordPlus | EPIDERMAL-GROWTH-FACTOR | - |
dc.subject.keywordPlus | NF-KAPPA-B | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | INDUCTION | - |
dc.subject.keywordPlus | GENE | - |
dc.subject.keywordPlus | INVASION | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | OVARIAN | - |
dc.subject.keywordAuthor | Akt pathway | - |
dc.subject.keywordAuthor | Fibronectin | - |
dc.subject.keywordAuthor | Poor prognosis | - |
dc.subject.keywordAuthor | Tamoxifen resistance | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.